- Global Pharma News & Resources

Amebiasis Treatment Market Size Estimation, Future Growth Insights, Share Analysis, Key Profile, Dynamics and Business Overview By 2026

SEATTLE, March 25, 2021, (PHARMIWEB) — Global Amebiasis Treatment Market

Amebiasis is an infection of the intestine caused by a parasite, called Entamoeba Histolytica. Symptoms of this disease include loose stool, abdominal cramping, and stomach pain. The condition is commonly found in regions with less developed sanitation facilities, for instance, certain parts of Asia Pacific, Central America, South America, and Africa. Amebiasis is mainly transmitted through water or food contaminated with Entamoeba Histolytica. Amebiasis could potentially lead to diarrhea (with or without blood) in both adults and children, leading to high morbidity and mortality rates. The organism, Entamoeba Histolytica, is capable of damaging several organs, following which a surgical intervention might be necessary, in case the colon and other tissues have undergone perforation. Amebiasis can be treated with some antibiotic, anti- parasitic, and antiprotozoal drugs, such as metronidazole, paromomycin, and tinidazole. Diagnosis of this disease is usually done by microscopic identification of the microorganism in a stool specimen.

Request Sample Copy of the Business Report:

Global Amebiasis Treatment Market Insights

Increasing regulatory approvals and launch of new drugs indicated for the treatment of Amebiasis are pivotal factors expected to supplement the growth of the global Amebiasis treatment market. For instance, in 2017, Dr. Reddy’s Laboratories received U.S. Food and Drug Administration (FDA) approval for its Minolira (minocycline) extended-release tablets, indicated for the treatment of a variety of bacterial infections and as adjunctive therapy in acute intestinal Amebiasis. Moreover, in 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched  Metronidazole Tablets, 250mg and 500mg, generic version of Flagyl manufactured by G.D. Searle, LLC’s, indicated for the treatment of amebiasis and a variety of anaerobic bacterial infections. In 2016, Mylan Pharmaceuticals Inc. received ANDA approval for its Doryx (Doxycycline Hyclate) Delayed-Release Tablets, 50 mg, indicated for the treatment of acute intestinal amebiasis. Furthermore, increasing prevalence of amebiasis in regions with poor sanitation facilities is projected to trigger the demand for its treatment, which in turn, would accelerate the Amebiasis treatment market growth in the near future. According to data published by International Research Journal of Biological Sciences in 2013, the prevalence of amebiasis among school children in Lafia, Nigeria, was around 26.7%. The highest prevalence rate of amebiasis was 40.0% among children Lafia. Therefore, high prevalence of the disease is attributed to poor environmental/drainage system, unhygienic methods of disposing sewage, and shortage of clean water supply.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Global Amebiasis Treatment Market – Regional Analysis

Africa is expected to show a significant growth in the global amebiasis treatment market over the forecast period, owing to high prevalence rate of amebiasis due to poor sanitation and low availability of clean drinking water. For instance, according to data published by United Nations Department of Economic and Social Affairs (UNDESA), in 2014, around 115 people in Africa die every hour from diseases linked to poor sanitation, poor hygiene, and contaminated water. In Sub-Saharan Africa around 40% of the 783 million people do not have access to a clean source of drinking water. Furthermore, Asia Pacific region is expected to show significant growth in amebiasis treatment market over the forecast period, owing to increasing prevalence of amebiasis in some rural areas of India and China. For instance, according to data published on National Health Portal of India, in 2015, amebiasis affected about 15% of the total population in India.

Global Amebiasis Treatment Market – Key Competitors

The leading players operating in the global Amebiasis treatment market include Pfizer Inc., Impax Laboratories, Lupin Pharmaceuticals, Inc., Sanofi, Actelion Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Inc., Heritage Pharmaceuticals Inc., Mission Pharmacal Co., Novel Laboratories, and numerous others. These players are currently focused on launching the generic versions of numerous branded medicines indicated for the treatment of Amebiasis. For instance, in 2017, Mayne Pharma Group Limited received FDA approval for its Doxycyline Hyclate IR Tablets, first generic to Acticlate. Doxycycline Hyclate 75 mg and 150 mg are tetracycline class drugs indicated for adjunctive therapy for acute intestinal Amebiasis.

To understand Research Methodology, please click

Market Taxonomy

By Drug Type

  • Metronidazole
  • Paromomycin
  • Tinidazole
  • Iodoquinol
  • Dehydroemetine
  • Chloroquine phosphate
  • Others

By Distribution Channel

  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Table of Content

Global Amebiasis Treatment Market Research Report
Section 1: Global Amebiasis Treatment Industry Overview
Section 2: Global Economic Impact on Amebiasis Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Amebiasis Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Amebiasis Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 25-Mar-2021